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Abstract
Cell lines are still a tool of choice for many fields of biomedical research, including oncology. Although cancer is a
very complex disease, many discoveries have been made using monocultures of established cell lines. Therefore,
the proper use of in vitro models is crucial to enhance our understanding of cancer. Therapeutics against renal cell
cancer (RCC) are also screened with the use of cell lines. Multiple RCC in vitro cultures are available, allowing in vivo
heterogeneity in the laboratory, but at the same time, these can be a source of errors. In this review, we tried to
sum up the data on the RCC cell lines used currently. An increasing amount of data on RCC shed new light on the
molecular background of the disease; however, it revealed how much still needs to be done. As new types of RCC
are being distinguished, novel cell lines and the re-exploration of old ones seems to be indispensable to create
effective in vitro tools for drug screening and more.
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Background
Cell line-based research had a major impact on the de-
velopment of cancer treatment allowing an innumerable
amount of effective drugs to be introduced into practice
[1]. Cancer cell lines, especially those in NCI-60 panel,
are the first target of preclinical drug screening that en-
ables the quick elimination of ineffective compounds
from further preclinical and clinical testing, requiring la-
boratory animals and patients [2]. Since 1955, the US
National Cancer Institute (NCI) has provided screening
support to cancer researchers worldwide. Until 1985, the
NCI screening program and the selection of compounds
for further preclinical and clinical development under
NCI auspices had relied predominantly on the in vivo
L1210 and P388 murine leukemias and certain other
transplantable tumor models. In June of 1984, the author
presented to the NCI Division of Cancer Treatment’s
Board of Scientific Counselors (BSC) a preliminary con-
cept of a disease-oriented in vitro primary anticancer
drug screen as a potential replacement for the P388 in
vivo primary screen; after the development of the 60 cell
lines panel, it was formally launched in 1990 and is
embodied in the present-day screen [3]. The ultimate
goal of this disease-oriented screen is to facilitate the
discovery of new compounds with potential cell line-
specific and/or subpanel-specific antitumor activity [4].
The 60 cell lines of the National Cancer Institute Anti-
cancer Drug Screen (NCI-60) constitute the most exten-
sively characterized in vitro cancer cell model. They
have been tested for sensitivity to more than 100,000 po-
tential chemotherapy agents and have been profiled ex-
tensively at the DNA, RNA, protein, functional, and
pharmacologic levels. Cell lines as a tool in biomedical
research have both advantages and disadvantages in
comparison with primary cultures and laboratory ani-
mals. First, they provide large numbers of cells available
for testing, while primary cultures typically have a lim-
ited lifespan and require regular access to donors [5].
Importantly, cell lines are a crucial tool in implementing
the 3Rs principle of animal research - Replacement, Re-
duction and Refinement [6] reducing the number of la-
boratory animals used during primary drug screening.
This provides ease and speed of inventions. At the same
time established cell lines represent a simplification of
natural phenomena, as they are deprived of multilateral
relations between different cell populations, microenvir-
onment and responses of the host [7]. This can be
partially overcome by culturing cells in complex three-
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dimensional systems or co-cultures, whaich better
mimics natural surroundings in the host, retaining the
ease of work and controlled conditions [8, 9]. However,
further testing in more relevant biological models is in-
dispensable to proceed to clinical trials but cell line re-
search will still underlaie most of them [10, 11].
Renal cell cancer (RCC) research has greatly benefited
from cell line studies. Cell biology studies enable an un-
derstanding of RCC biology and translational studies
[12–15]. To analyze homogeneous populations of cancer
cells and feasibly identify genetic changes (mutations,
gene expression) cell lines derived from tumor tissues
(nephrectomy and metastasectomy specimens) from pa-
tients with renal cell carcinomas are being established
[16]. The reported efficacy rate in establishing new cell
lines is 75% from fresh and from 35% frozen specimens
[16]. In a large study covering 498 successive attempts
to establish RCC cell lines, 63 were successful (12%)
[17]. The development of new drugs requires an appro-
priate model for testing; therefore the analysis of the ra-
tionale for choosing appropriate cell lines for RCC
research is an objective of this review. We focus on
popular RCC cell lines, their properties, and usefulness
but also note the issues that may be vital for RCC cell
line-based research.
RCC subtypes
Cancer sample (nephrectomy, metastasectomy) de-
rived cell lines are used as in vitro RCC models, and
it is important to remember that cell lines are in fact
genetic models of their parent tumor histology [18].
Different clinical characteristics and treatment suscep-
tibility are apparent between histotypes of RCC. Can-
cer cell lines in vitro preserve the unique genetic
aberrations of parent tumor from which they were
derived, and in long-term culture they acquire add-
itional specific alterations [18]. In culture, cells no
longer have easily identifiable morphological charac-
teristics used in the histological classification of
tumor specimens. As with primary RCC tumors, the
mutation status of cancer including VLH, cMET and
TP53 and a general marker immunohistochemistry
profile may serve to define the histotype of RCC cell
lines (Table 1). Molecular and cell biology researchers
using in vitro cell culture as experimental models
need to recognize that, like primary cancers, the
models used to study diseases genetics, biomarkers,
and drug activity/resistance must also be stratified.
RCC cell line-based studies are often hampered by a
lack of proper annotation of RCC lines. Disease-
specific studies need to incorporate cellular and
clinical contexts [19, 20]. Surprisingly, many basic
pre-clinical RCC studies employing functional re-
search on “renal cancer/renal carcinoma/renal
adenocarcinoma/renal cell cancer” cell lines do not
analyze the background of the investigated model and
analyze different subtypes of RCC together, including
wild-type cell lines and those harboring mutations (i.e.
VHL) and cell lines of different histotypes [21–23]. The
conclusions of such projects may be difficult to interpret,
and the value of potential therapeutic targets is rather
questionable, as is the true relevance to a particular RCC.
Confirming established histotype-specificity markers for
RCC cell lines should become the standard in planning
and executing experiments on renal carcinoma [23, 24].
Major improvements in the pathologic classification of
RCC have been reported over last 30 years. The first,
known only as renal cell carcinoma, was in the 1960s di-
vided into clear cell and granular histotypes. Currently
five traditional and well-defined subtypes of RCC are
known: conventional clear cell RCC, papillary (types 1
and 2) RCC, chromophobe RCC, carcinoma of the col-
lecting ducts of Bellini, and unclassified RCC and these
subtypes represent the majority of RCC cases diagnosed
[25]. Clear cell RCC (ccRCC) is the most common sub-
type of renal cancer and accounts for approximately 70–
75% of cases, so it cannot be assumed that all RCC-
derived cell lines represent ccRCC. Papillary RCC
(pRCC) is the second most common subtype of RCC
and is diagnosed in approximately 10–16% of cases;
pRCC is therefore expected among cell lines already in
research. In the case of cell lines established in the
1970s or 1980s, histology (based on specific mutations
and genetic changes) should be verified before any con-
clusions of the studies using cell lines are drawn. This
particularly applies to new drug developments that are
most often histotype specific [26].
In particular, pRCC was characterized in the 1980s as
tumors containing more than 75% of papillary structures
and not bearing 3p chromosomal loss on the contrary to
ccRCC. Later [27], it was found that two different sub-
types of papillary tumors may be distinguished (referred
as to pRCC Types 1 and 2). Genomic characterization of
types 1 and 2 papillary tumors is still incomplete. Inher-
ited forms of types 1 and 2 tumors are referred as to
hereditary papillary renal cell and hereditary leiomyoma-
tosis and RCC (HLRCC), respectively. Germline met
proto-oncogene (MET) and fumarate hydratase (FH) al-
terations are the hallmark of these cancer syndromes,
but are infrequent in sporadic cases [28, 29]. It also
needs to be underlined that the RCC subtype of clear
cell papillary renal cell carcinoma [30] has mixed charac-
teristics of both clear cell and papillary RCC, but pos-
sibly some of cell lines may represent this phenotype.
Chromophobe RCC (chRCC) is the third most com-
mon RCC subtype, and it was described for the first time
in the mid-1980s. Additionally, rare histologic RCC sub-
types were discovered in the 1990s and 2000s and
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include collecting duct carcinoma, medullary RCC,
translocation RCC, and mucinous tubular and spindle-
cell RCC. Recently, even more new subtypes have been
described- hybrid oncocytic chromophobe tumor, mu-
cinous tubular and spindle cell carcinoma, multilocular
cystic clear cell RCC of low malignant potential, carcin-
oma associated with neuroblastoma, and renal medullary
carcinoma [25, 31, 32]. Nevertheless, one should also
not forget RCC types that were approved in 2013 by the
International Society of Urological Pathology (ISUP)
Vancouver Consensus Statement including five more
epithelial tumor subtypes: the micropthalmia (MiT) fam-
ily translocation RCCs (Xp11 translocation RCC), tubu-
locystic RCC, acquired cystic disease-associated, RCC
clear cell tubulopapillary RCC, and hereditary leiomyo-
matosis–RCC syndrome-associated tumors. Next, three
RCC subtypes were given provisional status- thyroid-like
follicular carcinoma of kidney, succinate dehydrogenase
B deficiency-associated RCC, and anaplastic lymphoma
kinase translocation RCC [31, 32].
Table 1 Differentiation of RCC subtypes






Oncocytoma Xp11.2 translocation RCC
VHL
mutation
+ (~90%) - - - - -
cMET
mutation
- + - - - -
TP53
mutations
- - - + - -
Other
mutations
PBRM1 (~50%), BAP1 (~15%),
SETD2 (~15%)
NRF2, CUL3 FH - Mitochondrial
complex I genes
translocations of Xp11.2 (TFE3)
or 6p21 (TFEB)
CK8 +/- + + +/- + ND
CAIX + +/- + - - +
CAM 5.2 + + + + + -
CD10 + + + +/- +/- +
CD15 + + + - + ND
CK18 + + + + + ND
EMA + + + + + -
GST-alpha + - - - - ND
PAX2 + + +/- - + +/-
PAX8 + + + + - +
RCC Ma + + +/- - - +
VIM + + + - - +
AMACR - + + - - +
CD117 - - - + + ND
CK7 - +/- -/+ +/- - +/-
CK19 - - - - - +/-
CK20 - - - - - -
c-KIT - +/- +/- + + ND
CLDN7/8 - - - + + ND
E-cadherin - + +/- + - +
EpCAM - - -/+ + +/- ND
Ksp-cad - - - - + +
PVALB - - - + +/- ND
TFE3 - - - - - +
SMA - - - - + ND
Legend: AMACR α-methylacyl coenzyme A racemase, CAIX carbonic anhydrase IX, CK7 cytokeratin 7, CLDN7/8 claudin 7/8, EMA epithelial membrane antigen, GST-
alpha glutathione S-transferase alpha, EpCAM epithelial cell adhesion molecule, Ksp-cad kidney-specific cadherin, PVALB parvalbumin, RCC Ma renal cell carcinoma
marker, SMA smooth muscle action, TFE3 Transcription factor E3 - transcription factor binding to IGHM enhancer 3, PAX2/8 paired box gene 2/8, VIM vimentin, ND
no reported data
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To distinguish RCC subtypes, genetic analysis may
be employed. The von Hippel-Lindau (VHL) gene is
known to be most often mutated in renal cell carcin-
oma of clear cell type (ccRCC) in up to 90% of spor-
adic ccRCC cases [33] and multiple surprising and
contradictory reports on the VHL gene status in com-
mon RCC cell lines have been published (Additional
file 1: Table S1). Moreover recently three other tumor
suppressor genes PBRM1 (mutated in ~50%), BAP1
(~15%), and SETD2 (~15%) were defined as specific
for the ccRCC subtype. PBRM1, also known as
BAF180 or Polybromo, is a member of the PBAF
SWI/SNF chromatin remodeling complex. VHL,
PBRM1, BAP1 and SETD2 are allocated on chromo-
some 3p. BAP 1 is a BRCA1- associated protein-1
(ubiquitin carboxy-terminal hydrolase). Mutations in
BAP1 and PBRM1 in ccRCC tend to be mutually
exclusive [34].
This in vivo heterogeneity of RCC should be mimicked
in vitro; a wide panel of cell lines with different charac-
teristics is needed to provide us with a tool for both
basic and applied research.
RCC cell lines used in research
The number of available RCC cell lines is impressive:
more than 20 cell lines are widely used- deposited in cell
banks- and dozens of others were established and used
for research in selected laboratories (Fig. 1) [16]. The
most popular RCC cell lines are delivered by ATCC and
other certified cell banks (Additional file 1: Table S1).
Most cell lines were established between the mid-1970s
till the late 1980s, when subtypes of RCC including clear
cell, papillary, or chromophobe RCC were not yet distin-
guished; therefore, all the subtypes may be represented
among RCC cell lines. Many researchers currently refer
generally to RCC or renal carcinoma when describing
their laboratory model. Although this is true, it regret-
tably narrows conclusions that can be drawn from their
research, thus limiting the translational potential of in
vitro studies. However, a growing amount of data can
help to categorize cell lines established before 1995 into
correct RCC subtypes as the cell lines genetic profile is
analyzed and cells lines are characterized for markers of
particular RCC subtypes with multiple methods includ-
ing immunohistochemistry (IHC), gene sequencing, and
xenografted tumors histology analysis [35, 36]. The
proper initial molecular characterization of cell lines is
indispensable to provide later in vitro tools to study gen-
etic and cellular events underlying carcinogenesis, dis-
ease progression, and/or drug activity [23, 37–39].
Often, information on original patients- cell line donors-
is fragmentary and more precise characteristics of estab-
lished cell lines come with time, thanks to cell biology
and genetic studies [28, 33]. Most recently, interesting
cell lines representing novel RCC subtypes have been
established, including NCCFH1 for hereditary papillary
renal cell carcinoma type 2 [40] or the S-TFE cell line
for Xp11 translocation renal cell carcinoma [41]. In
Additional file 1: Table S1, we collected various informa-
tion available for over 60 cell lines- including the source
of starting material, basic genomic data, and database
tools that might be useful in designing RCC cell line-
based experiments.
ACHN cell line
The ACHN cell line represents an uncertain RCC histo-
type (Fig. 1). It was established from pleural effusion and
models metastatic disease. In early xenograft studies, tu-
mors were described as poorly differentiated clear cell
[42] however, a more recent genomic comparison sug-
gests papillary characteristics of ACHN [43]. Moreover,
this cell line harbors a c-met polymorphism that is spe-
cific for papillary RCC [44]. Chromosome aberrations in
ACHN cells also resemble those of papillary tumors
[45]. Yet, gene expression analysis revealed similarities
to clear cell tumors, especially when concerning the
MYC pathway [29]. No mutations in VHL and HIF-1α


















Fig. 1 Classical RCC cell lines as models of different RCC subtypes and disease stage
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mRNA in ACHN cell line, could confirm non-clear cell
histology [46].
A-498 cell line
A-498 is a “classical” RCC cell line belonging to the
NCI-60 panel and is therefore widely used in cancer re-
search. Mutated vhl [46, 47] would suggest a clear cell
subtype; however, a study by [48] detected no mutation.
In addition, [49] claimed that A-498 is of papillary ori-
gin, as xenografts exhibited such histology. To some ex-
tent this observation was confirmed by chromosome 8
and MYC analysis [29]. Nonetheless, this issue was not
significantly recognized by scientific community and
most researchers use it as a model of ccRCC [47, 50, 51]
with rare exceptions [52].
786-O cell line
786-O, established as one of the first RCC cell lines, has
many characteristics of ccRCC and is used most com-
monly in RCC-focused research (Fig. 1). The 786-O
RCC line is defective in VHL expression, as it harbors
mutated VHL [53, 54] with altered HIF and VEGF (Vas-
cular endothelial growth factor) pathways [46] and gives
rise to clear cell tumors in nude mice [55, 56]. In this
RCC model the vast majority (122/160) of genes induced
by hypoxia in wt-VHL transfected 786-O (VHL+) cells
are not significantly up-regulated in VHL mutated 786-
O cells, confirming that the loss of VHL is not equiva-
lent to hypoxic exposure and that in RCC, the VHL
tumor suppressor has a distinct role from its activity in
the hypoxia-inducible pathway [57]. Interestingly, side
populations (SPs) of higher tumorigenicity were ob-
served in this cell line, proving its usefulness in cancer
stem cell studies [58, 59]. Surface receptors also confirm
the ccRCC phenotype of 786-O cells, as these cells are
positive for CD10 [60] and vimentin [61]. These cells
produce high levels of VEGF [46] as well, which is char-
acteristic of ccRCC. This cell line can be used to model
bone metastasis in RCC- 786-O cells injected into nude
mice, both directly to the tibia or to the cardiac ven-
tricle, cause bone destruction and vascularization [62,
63]. A subline derived from such metastatic tumors can
be cultured in vitro in 3D systems that retain bone me-
tastasis characteristics [64].
Caki-1 cell line
Caki-1 is a widespread model line of metastatic ccRCC
(Fig. 1). While harboring wild-type vhl, it was shown to
produce tumors of clear cell histology in nude mice,
both by the total population and SP cells [65]. High
VEGF production [66] (especially in hypoxic conditions
[56]) in those cells is also a hallmark of ccRCC. Interest-
ingly, this cell line was also proposed as a model system
of proximal tubule epithelium, as in culture, cells can
form a polarized layer with morphological, physiological
and biochemical characteristics of functional, well-
differentiated kidney tissue [67].
Caki-2 cell line
Caki-2 was established from a primary tumor of the kid-
ney. This cell line was primarily defined as the ccRCC
cell line (Fig. 1) that expresses wild-type pVHL but does
not express HIF-2α. However, a low expression of HIF-
1α is detected in this cell line for unknown reasons [46].
The recent evaluation of tumors formed by Caki-2 in
nude mouse in orthotopic and sub-cutaneous implanta-
tions revealed cystic papillary tumors with microvilli and
microfilaments, few mitochondria, lysosomes or lipid
droplets, and multilamellar bodies [68–70]. Although
the Caki-2 cell line has been treated as a model for pri-
mary ccRCC, a growing amount of data suggests that it
is a cell line of papillary RCC. These cells express high
levels of MET and LRRK2 [71] and harbor chromosome
8 aberrations [29] characteristic ofr papillary RCC. Inter-
estingly, reports on VHL gene status of this cell line are
inconsistent– some researchers detected no mutations
[46], while others [47, 48] reported mutations in α-
domain of VHL, which may imply the clear cell hist-
ology of Caki-2. Such misleading observations have led
to non-uniform use of this cell line–it is now widely
used both in clear cell RCC [66, 72, 73] and papillary
RCC [69–71, 74] research. Finally, it is generally de-
scribed as clear cell RCC by most cell banks, which may
lead to misinterpretation.
769-P cell line
The 769-P cell line, established along with 786-O by
[75], harbors mutated vhl and secretes high levels of
VEGF, suggesting a ccRCC phenotype (Additional file 1:
Table S1 for ref ). These cells contain a SP of higher
tumorigenicity that can create tumors even after serial
passage in nude mice retaining their original histological
characteristics [76]. However, the validity of this cell line
in xenograft studies is limited; injected subcutaneously
[56] or i.v. [55], they failed to form tumors in some
models.
RCC4 cell line
Another interesting cell line is RCC4, a vhl mutant
[77, 78] derived from a primary tumor widely used as
a model for VHL-dependant mechanisms, witha com-
mercially available counterpart cell line with restored
wild-type gene [79]. It is used [80–83] for both in
vitro and in vivo experiments, as RCC4 cells are
tumorigenic in nude mice. Unfortunately, no data on
the original patient can be found; supposedly the cells
were obtained by Prof. C.H.C.M. Buys, Department of
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Medical Genetics, University of Groningen, Groningen,
the Netherlands.
SMKT-R cell lines
SMKT-R1, SMKT-R2, SMKT-R3 and SMKT-R4 are cell
lines established in Sapporo Medical College from pri-
mary lesions of RCC from xenotransplantable tumors at
passage 2 or 1 in nude mice [84]. Vhl is mutated in cell
lines SMKT-R2 and SMKT-R3 [48], and in SMKT-R2
and SMKT-R3 HIF-α proteins are expressed [85].
SMKT-R3 original tumors are characterized as papillary
type and granular cell subtype, and the level of secreted
VEGF is lower than in SMKT-R2 line [86] confirming
the non-ccRCC histology of this cell line. Research on
the SMKT-R cell lines confirms that RCC cell lines can
retain the histology of the original tumor after in vitro
culture and passage in nude mice.
Memorial Sloan Kettering Cancer Centre cell line
collection
The metastatic dissemination of cancer may be par-
tially recapitulated in vitro with analysis of multiple
metastatic loci and metastasis-derived cell lines. This
in vivo heterogeneity of tumors can be mimicked in
vitro with use of a panel of cell lines in the place of
multiple biopsy derived samples [87]. The Memorial
Sloan Kettering Cancer Centre provides an RCC re-
pository with over 30 primary tumor-derived and 15
metastatic tumor-derived cell lines (SK-RC panel) col-
lected between 1972 and 1987 [17]. The MSKCC
panel covers cell lines obtained from tumors that de-
veloped in the most common RCC metastases loci,
including the adrenal glands (SK-RC-45), lymph nodes
(SK-RC-18, SK-RC-26b), lungs (SK-RC-26a SK-RC-31,
SK-RC-38 SK-RC-54), bones (SK-RC-42, SK-RC-46),
soft tissue (SK-RC-17, SK-RC-39), and the brain (SK-
RC-9, SK-RC-13). This collection consists of samples
with different features; however, the molecular
characterization of particular cell lines is still incom-
plete (Additional file 1: Table S1). The SK-RC-45 line
was used to study immune responses in RCC and the
induction of T cell apoptosis [88, 89], while SK-RC-42
was shown to contain cancer stem cells (“CSCs”) [90].
These cell lines express either HIF-2α only (SKRC-21,
SKRC-17) or both HIF-1α and HIF-2α (SKRC-7,
SKRC-10, SKRC-52) [91].
Laboratory specific RCC cell line collections
3Thirty cell lines from primary tumors as well as four
lines from metastatic tissues taken from 31 patients were
established in the National Cancer Institute in Bethesda
(UOK 101–131 cell lines). Sixteen of the cell lines were
derived from tumors composed predominantly of clear
cell RCC, three were granular cell RCCs, and one
papillary type (UOK112). The remaining tumors were of
mixed types including clear and granular cells, clear cell
+ granular and sarcomatoid cells (UOK 105, 117, 119,
123 and 127), or clear cell and papillary (OUK 120). Cell
line phenotypes, including morphology, in vitro growth
characterization, and tumorigenicity in nude mice were
determined for these cell lines [16]. Another seven RCC
cell lines were established in the Korean Cell Line Bank
of Cancer Research Center and Cancer Research Insti-
tute. In particular, five cell lines were derived from clear
cell RCC (SNU-228, -267, -328, -349, and -1272), one
from granular RCC (SNU-482), and one from mixed
clear and granular RCC (SNU-333). The mutational sta-
tus of cell lines was confirmed for von Hippel-Lindau
(VHL), p53, TGF-beta type II receptor (TGF-betaRII),
hMSH2, and hMLH1 genes [92]. More recently, Chinese-
origin cell lines named NRCC from the primary ccRCC
and MRCC from the metastatic ccRCC were established
from the primary tumor of a 49-year-old male ccRCC pa-
tient and the metastatic tumor of a 62-year-old male with
ccRCC. The morphology of cell lines along with the doub-
ling times, colony formation rates, invasion assay,
anchorage-independent growth, cytogenetic characteris-
tics, and expression of CD105, CD133, CD44, CD24,
CD56, CD99, and CD74 markers as well as N-cadherin, E-
cadherin, and vimentin were described and have shown
that NRCC cells displayed more epithelial characteristics,
while MRCC cells are mesenchymal-like [93].
RCC cancer stem cell cultures
Specific subpopulations of cancer cells are available for
culture. In particular cancer stem cells referred to as
tumor-initiating cells are currently becoming available.
In particular, donor specific kidney cancer cells derived
from primary tumors cultured in stem cell-promoting
media are enriched in CSCs (Promab cat. No. CF100107,
Celprogen cat. No. 36117-44). The role of CSCs in RCC
has been reviewed elsewhere [94], as they are potential
treatment targets [95]. They are putatively tumor-
initiating cells that promote disease development and
progression and may be distinguished using different ap-
proaches. CSCs can be discriminated based on their
unique features; in different cancers, in comparison to
other tumor cells, they have elevated aldehyde dehydro-
genase (ALDH) activity, increased glycolysis and glycine/
serine metabolism or low concentrations of reactive oxy-
gen species and ATP, the ability to form spheres, and a
reduced level of proliferation. Such functional character-
istics can be used to selectively isolate subpopulations of
cancer cells [96–99]. Moreover, due to the increased ac-
tion of ABC transporters, CSCs are more resistant to
drug treatment, which enables the separation of CSCs
from other tumor cells based on the increased efflux of
ABC-dependent dyes (Rhodamine123 or Hoechst33342)
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as a dye-negative side population (SP) [98, 100]. In RCC,
CD105 and CD133 surface markers are also suspected
to identify cells with stem properties [101, 102]. CSCs
express genes typical for multi/pluri-potent cells; Oct4,
Sox-2, Nanog, and Bmi-1 [98, 103] and are shown to
have increased tumorigenicity and clonogenicity. In
stable cell cultures of RCC cells, cancer stem cells have
been identified, which primarily reflects the unexpected
heterogeneity of cell culture in vitro. In 769-P, ACHN,
Caki-1, SMKT-R2, and SMKT-R3 cell lines, the SP of
Hoechst33342 negative cells was shown to express CSC
properties [76, 104]. The ACHN line CSC subpopulation
is Hoechst33342-negative and ALDH-positive [98], while
Caki-2 CSCs are also ALDH-positive and form spheres
[99]. The 786-O cell line is also shown to bear the CSC
subpopulation, as confirmed by Rh123 fluorescent inten-
sity based isolation [105]. At the same time, SK-RC-42
cells cultured in spheres have features of CSCs [90].
However, methods in CSCs research are not yet uniform,
and some contradictory data complicate the explanation
of their role in RCC. In particular, [105] showed that
Rh123low cells show stronger CSC properties than the
Rh123high population that could be suspected to group
stem cells.
Normal renal proximal tubule cells
Primary cultures of normal human epithelial cells of
proximal origin derived from the renal cortex have been
shown to present very homogeneous morphology in
vitro [106]. If normal tissue originating from the same
donor is not available, RPTEC cells are used as the con-
trol cell line for the comparative analysis of cancer and
normal renal cells [57]. RPTEC cells are human renal
proximal tubule epithelial cells that are derived from
normal or diseased (e. g. diabetic) donors [107]. As pri-
mary cells, they have a limited lifespan, but usually can
reach at least eight passages maintaining typical epithe-
lial, cobblestone morphology and the expression of epi-
thelial and renal markers like E-Cadherin, CK, or ZO-1
[108, 109]. These cells are also available as immortalized
lines: HK-2 and RPTEC/hTERT. The former was trans-
duced with human papilloma virus (HPV 16) E6/E7
genes [110] while the latter ectopically expresses the
catalytic subunit of telomerase (TERT) [111]. These
modifications enable the cells to be cultured continu-
ously constituting a convenient control for RCC cell
lines. Many studies show that the cells are genomically
stable and most functional characteristics remain typical
for RPTEC [111]. RPTECs are used to model basic kid-
ney functions and renal diseases. Nephotoxicity [112],
the efflux of drugs [113], responses to environmental
toxicants [114] or renin-angiotensin system (RAS) sig-
naling [115] can be studied with the use of these cells. In
RPTECs, the steady-state amount of VHL protein is
strictly regulated by the cell density, and the cellular
VHL content is more than 100-fold higher in dense cul-
tures than in sparse cultures [116].
Total kidney isolates are also available (e. g. Applied
StemCell, cat. no. ASE-5186); after the dissociation of a
healthy renal sample, all cells are frozen which allows
various cell types to be cultured without direct access to
donors.
Another widely used non-cancer renal cell line is
the HEK293 cell line. Generated in 1977 by the viral
transformation of human embryonal kidney cells,
[117] HEK293 cell line is a widely used expression
tool [118]. Although studies show that these cells have
many features of neuronal cells [119, 120], they are still
used as a model for kidney physiology [121, 122]. There-
fore, they may be used as convenient controls in RCC
in vitro research as well, but caution is needed for
interpretation [73, 123].
RCC cell lines specific for bone metastasis-oriented
research
RCC cell lines have also been developed as tools to
study specific phenomena in RCC. In particular, a
model to study the biology of the bone metastasis of
renal cell carcinoma has been established. This cell
line induced osteolytic lesions in nude mice after
injecting into the tibia. RBM1 cell line cells expressed
high levels of cytokines involved in osteoclast activa-
tion and bone resorption- parathyroid hormone-
related peptide, interleukin-6, and macrophage
colony-stimulating factor. Moreover, cells were con-
firmed to express EGFR and c-MET [124]. SK-RC-42
and SK-RC-46 also represent bone metastasis-derived
cell lines [17], as well as the CRBM-1990 cell line
[125], while ACHN and 786-O cells transplanted into
the left ventricle establish bone metastases [126, 127].
If studied after injection, bone metastasis-derived 786-
O cells (Bo-786-O) compared to parental 786-O cells
or cells that localized in the liver or lymph nodes had
significantly overexpressed cadherin-11, but not
CXCR4, HIF-1α, VEGF, angiopoeitin-1, Tie2, c-MET,
PTHrP, IL-6 or RANKL [128]. Sunitinib prevents the
growth of ACHN cells in a bone metastatic model.
The number of osteoclasts in sunitinib-treated
ACHN-bearing mice is significantly lower than that in
non-treated mice [126].
Other RCC cell lines
RCC subtypes less frequent than clear cell and papillary
are even more difficult to study in vitro as specimens are
obtained rarely. Recently, several cell lines were devel-
oped to model HLRCC; a rare genetic disorder that
manifests by cutaneous and uterine leiomyomas and kid-
ney tumors. Metastatic NCCFH1, UOK262, and primary
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UOK268 cell lines are FH deficient and can serve as
models for hereditary papillary type 2 RCC [40, 129,
130]. An in vitro model for Xp11.2 translocation carcin-
oma has recently been established as well. S-TFE cell
line is tumorigenic in nude mice and has fused TFE3
and ASPL genes [41].
Large scale molecular data and RCC cell lines
Some RCC cell lines, mostly present in NCI-60, were
used in whole genome analyses. Mutational, copy
variant, and expression analyses available for cells
lines are provided as links to databases in Additional
file 1: Table S1. The Cancer Genome Atlas (“TGCA”)
provided much valuable information on RCC charac-
teristics that can now be used in cell line-based re-
search. TGCA analyses identified vhl, pbrm1, bap1,
setd2, kdm5c, pten and mtor as the most frequently
mutated genes in ccRCC [131]. vhl mutant cell lines
are easily accessible; 786-O, 769-P, RCC4 (with rein-
troduced vhl control cell line available), are the most
widely studied models for VHL role in RCC. Apart
from gene mutation, vhl promoter region methylation
often occurs in ccRCC samples which effects in no
protein expression. Such a phenomenon was reported
for SK-RC-54, 769-P, and A-704 [132].
Classical cell lines were recently verified for PBRM1
expression status and confirmed ACHN- positive, 786-
O– positive, and A-704– negative. The ACHN cell line
expresses the protein, but harbors a heterozygous non-
sense mutation, while 786-O, 769-P, Caki-1, and A-498
express wild-type PBRM1 [133, 134]. The PBRM1 muta-
tion is also reported in Caki-2 and A-704 lines; loss-of-
function gene mutations in A-704 and the deletion in
exon 17 of the PBRM1 gene in Caki-2 [135] results in
no protein expression [133, 134, 136]. Mutations have
also been detected in OS-RC-2 and RCC-ER (see Add-
itional file 1: Table S1 for ref ) cell lines; however, the
former was reported to express PBRM1 protein [133].
The strong and moderate expression of PBRM1 was also
confirmed in the next 16 cell lines, including normal hu-
man embryonic renal cell lines (HEK 293 and 293T) and
human renal proximal tubular epithelial cells (HK2) as
well as cancer cell lines- 769-P, A-498, KC12, Caki-1,
SW156, and SLR21-26 [133]. The knockdown of PBRM1
in cells with wild-type gene increased the proliferation,
migration and colony formation abilities [137], support-
ing this gene’s important role in RCC progression, as the
loss of PBRM1 was correlated with a worse disease out-
come in patients [133].
BAP1 mutants are available as UM-RC-6, 769-P, and
SN12C cell lines [138]; however, 769-P cells still produce
the protein [139]. The reintroduction of the wild-type
gene reduced cell proliferation and sensitized cells to
treatment, and it was proposed that BAP1 is a tumor
suppressor, as gene loss is associated with patients with
higher-grade RCC [139]. SETD2 mutations have also
been detected in A-498, A-704, Caki-1, and RCC-ER
[140–142], PTEN mutations in 786-O, and OS-RC-2,
while no mutated RCC cell lines could be found for
KDM5C. An mTOR mutation was found for SNU349
and RCC-ER cell lines only (see Additional file 1: Table
S1 for ref ). Studies on SETD2-defective RCC cells
proved that the mutation of this gene affects DNA repair
and may correlate with in vivo disease progression [143].
Chromosome alterations are also common in ccRCC
with the loss of the 3p chromosome (containing vhl,
pbrm1, bap1, and setd2), 14q loss (hif1a), or 5q gain be-
ing the most frequent [131]. However, the chromosome
analysis of RCC cell lines is not readily available; a 5q
gain was observed in most RCC cell lines tested by [144]
apart from A-498. Chromosome 3p loss was reported in
several UOK RCC cell lines: UOK108, 121, 125, and 127
[145]. Simultaneous losses in 3p and 14q were observed
in 769-P, 786-O, A-704, and Caki-1 [146, 147].
In the case of pRCC, TCGA indicated met, setd2, nf2,
kdm6a, smarcb1 and fat1, bap1, pbrm1, stag2, nfe2l2,
tp53 genes being the most frequently mutated among
patient samples [148]. The UOK112 cell line derived
from pRCC patient [16] was studied in the context of
HGF/MET signaling; however, no data on met status
could be found [149]. Interestingly, Caki-1 harbors a
mutation in met (COSMIC database). As mentioned
above, ACHN cells have a MET polymorphism (by some
also referred to as a mutation [150]), but protein was de-
tected and can be phosphorylated [151]. This cell line
was also shown to contain an NF2 mutation, together
with SN12C, while Caki-1, A-704, 769-P, TK10, 786-O,
A-498, and OS-RC-2 were confirmed to be wild-type for
NF2 [142]. A KDM6A mutation was reported for the
SN12C cell line only (COSMIC database), but no alter-
ations in the methylation of gene promoter was observed
in 5 other cell lines (786-O, 769-P, A-498, ACHN, and
Caki-1) by [152]. A FAT1 mutation was found in Caki-1,
OS-RC-2, SN12C, RCC-FG2, and TK10 (COSMIC data-
base) but no functional analysis of this gene in in vitro
RCC was reported.
Chromosome aberrations present in pRCC include
chromosomes 7 and 17 gains and 9p loss [148]. In the
case of cell lines, Caki-2 and ACHN cells show a gain in
genes located on chromosomes 7 and 17 and 9p loss,
which may be an additional clue confirming the papillary
origin of these cells [146, 153].
TP53 tumor-suppressor mutations, present in 50% of
tumor cases in general, are less frequent in RCC (around
20% cases [154]), but confirmed in 786-O, A-498 (COS-
MIC and CCLE databases),,SN12C, TK10 [155] and re-
ported as wild-type in ACHN, Caki-1, and Caki-2 [156].
Varied expression of the protein is visible in cell lines,
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which corresponds with in vivo data, as p53 over-
expression occurs in later stages of the disease [157] and
to some extent correlates with poor prognosis [158]. A
relatively high expression of p53 was observed in ACHN,
Caki-2, UOK121, and UM-RC-6 and low in A-498 (al-
though mutated) [159, 160]. Other genes, established by
TCGA studies to be often mutated in RCC, have been
less frequently studied with the use of RCC cell lines,
and no detailed information on gene status could be
found.
RCC cell lines in xenograft studies
The clinical translability of cell line experiments relies
on valid animal models. They provide complex platforms
for studying oncogenesis and the effectiveness of thera-
peutic approaches and, enable the verification of cell
lines’ tumorigenicity. While tumorigenic cells can be im-
planted into the same species (allografts) or another spe-
cies (xenografts), we will focus on immunocompromised
experimental animals that are injected with human cell
lines. The wide application of this approach in oncology
studies followed the discovery of two groups of immuno-
deficient animals: “nude” mice [161] and later severe
combined immunodeficient (severe combined immuno-
deficiency; SCID) mice [162].
Athymic nude mice are hairless, an effect of the
Foxn1nu (Forkhead box protein N1) mutation, but more
importantly they lack a thymus and are T-cell deficient
but produce functional B-cells [163]. This is not the case
with SCID mice that have a single nucleotide poly-
morphism (Prkdcscid) within the DNA-dependent pro-
tein kinase of the catalytic polypeptide Prkdc gene. This
mutation affects both T and B lymphocytes [162]. SCID
rodents display less pronounced immunoreactivity than
athymic nude mice to implanted cancer cells that results
in greater receptivity to tumor xenotransplantation
[164]. Recently, several promising transgenic models
have become available, including humanized NSG mice
[165]. Still, most of the available data on xenografted
RCC cell lines comes from the athymic nude mice
model.
The nature of the outcome of animal experiments
strictly relies on the place and route of cell inocula-
tion. Ectopic tumor xenograft models employ sub-
cutaneous (s.c), intraperitenoeal (i.p.), intravenous
(i.v.) or intramuscular (i.m.) implantation of tumor
cells. While advantages are the approach’s simplicity
and reproducibility, an obvious disadvantage of this
approach is the non-physiologic growth location. An
alternative approach, the orthotopic xenograft model,
involves the implantation of a tumor into the origin-
ating tissue site of the cancer in rodents. In the case
of RCC, the widely accepted implantation site is the
renal subcapsule [166, 167]. It is believed that
orthotopic tumor implantation more closely simulates
the microenvironment of the original tumor [168].
However, orthotopic xenograft models have some
additional disadvantages that could be crucial in RCC
research: they are more technically challenging and
may have highly variable tumor take rates and growth
rates; they could also result in significant animal mor-
bidity due to the surgical implantation of tumor cells
[168]. Importantly, the monitoring of tumor growth is
also more challenging in orthotopic models. All these
difficulties have led to subcutaneous ectopic implant-
ation being the most widely used approach in RCC
cell lines animal research.
Ectopic xenograft models of athymic nude mice with
various genetic backgrounds have been extensively used
for studying established RCC lines, including 769-P, 786-
O, Caki-1, SK-RC-38, SK-RC-42, SK-RC-44, SK-RC-45,
SK-RC-46, and others [17, 55, 169–173]. As summarized
in Additional file 1: Table S1, most of the cell lines de-
scribed in this article were proven to be tumorigenic in
nude mice. The implanted tumors normally become
palpable within 5 days and reach a volume of 100 mm3
in 2 weeks [169–171]. Implanted established cell lines
xenografted into nude mice preserve essentially the same
histology as the primary tumors [174]. In addition,
orthotopic xenotransplantation of Caki-2 into nude
mouse produces tumors that closely resemble histology
of human RCC.
Generally, xenografted tumors are considered as not
producing metastasis in most cases. Sharkey and Fogh
[175] studied 106 malignant human tumor lines and ob-
served metastasis in only approximately 1%. Such factors
as tumor size and growth rate and age and sex of the
host mouse appear unrelated to metastasis [167]. How-
ever, the incidence of metastasis is increased in SCID ro-
dents [176]. Moreover, the route of injection into nude
mice affects the metastasis incidence. Naito et al. [167]
indicated that even in highly metastatic cells, i.v. injec-
tion did not yield significant metastasis, but the injection
of cells orthotopically into the renal subcapsule resulted
in extensive metastasis to the lungs and in all peritoneal
organs. However, Strube et al. [127] were successful in
generating remarkable metastasis to the bone by inocu-
lating human 786-O cells into the left cardiac ventricle
of athymic nude mice. Caki-1, A-498, and 786-O
injected intravenously produced metastasis very rarely in
nude mice as well as in NOD SCID [177].
Finally, some cell lines fail to be tumorigenic in nude
mouse; 769-P, SK-RC-7, TK 10, TK 164 UM-RC-6, or
UOK108 [17, 145, 172, 178, 179]. Tumorigenicity in ani-
mal models depends on the intrinsic capability of the
tumor line employed. However, these results should be
interpreted with some caution, as potential failure could
also rely on the specific strain or age of animals [180].
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Still, precisely designed and controlled xenograft experi-
ments remain a powerful and useful tool in RCC
research.
Future of RCC cell line based research
Despite the undisputed profits that translational medi-
cine has gained from research conducted on cell lines,
several concerns have arisen regarding the extent to
which cell line results can be trusted [181–183]. Despite
its limitations, as a cell line does not strictly resemble an
in vivo tumor [184], the proper description of widely
used cell lines is indispensable. Currently, new RCC cell
lines are still being established. The isolation of cells
from normal and tumor samples can be performed with
various protocols [107, 185]. These can be used either
for primary cultures [186] or to establish new cell lines
[125]. Unfortunately, newly established cell lines rarely
receive recognition in the RCC community. Most stick
to widely known cell lines, such as: 786-O, 769-P, Caki-
1, or ACHN. At the same time, the interpretation of re-
search on some of these cell lines seems to be challen-
ging and may require re-interpretation. As described
above, data on particular cell lines, like most scientific
information [187], grows cumulatively, and at times we
need to redefine primary assumptions (e. g., cancer type)
and consequently interpreted phenomena. For instance,
if the Caki-2 cell line is indeed a model of papillary
RCC, reviewing past studies may shed new light on the
molecular background of this particular cancer subtype.
As papillary RCC research is rather underrepresented
[188], this would be of value for scientists and patients.
Cancer is a complex disease shaped by changes in cell
functions, but also intrinsic signaling inside the tumor
and extrinsic interactions with other cells of the host as
well as various components of the local microenviron-
ment. Such a multiplex disorder is very difficult to inter-
pret, and cell line research does not always reflect
cancer diversity. The limitations of the validity of cell
line cultures apply also to RCC. To increase the useful-
ness of cell lines for RCC discovery, complex in vitro
models have been designed. It was shown that samples
from RCC patients cultured as 3D organoids create
structures that closely mimic in vivo tumor, serving as a
useful model for personalized drug screening [186]. 3D
cultures for cancer studies is a hot topic that has been
reviewed recently in different aspects [189, 190]. Such
structures can also be created by cell lines; 3D cultures
have been shown to be a better model of in vivo mecha-
nisms in cancer than standard 2D techniques [191]. The
use of established cell lines would allow high throughput
platforms to be created that are useful for effective drug
screening [190, 192]. Such methods are of need in RCC
research; however, to create a valid in vitro screening
tool properly characterized cell lines are indispensable.
Conclusions
When conducting research using established cell lines,
one should carefully study the data on their establish-
ment and subsequently available characteristics. Thor-
ough data on original patients has not been was
provided consistently in prior research; however, mod-
ern molecular analysis helps to characterize cell line
features. Certain RCC specimens are underrepre-
sented, such as: papillary and chromophobe RCC,
metastatic ccRCC (especially tissues that are most
often affected in vivo; lungs, bones), and early stage
tumors. When establishing new cell lines, it is essen-
tial to follow the best available guidelines, e. g.
reviewed elsewhere [193]. Thorough data on original
patients’ tissue in terms of histological and molecular
characteristics should be collected, and subsequent
cell line stability should be monitored. A panel of
well-characterized RCC cell lines that reflect in vivo
heterogeneity in terms of different subtypes, grades,
and drug resistance would arm us with a screening
tool to test new therapy strategies and understand the
molecular background of RCC subtypes.
Take-home message
 Molecular profiling of RCC cell lines is not always
available, which may limit the clinical translation of
in vitro research; back checking of model cell lines
for typical RCC features is needed
 research on numerous cell lines with relation to
healthy tissues can increase the clinical value of
RCC cell line research; familiarity with their features
is indispensable to draw accurate conclusions
 Additional RCC cell lines and culture models are
needed to mirror in vivo heterogeneity
 When establishing new RCC cell lines thorough
characterization of OP data and subsequent culture
are indispensable to create a useful in vitro tool
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